JPRN-jRCT2033220367招募中Unknown
ong-term observational study of Gene Therapy for Parkinson's disease
akajima Takeshi0 个研究点目标入组 12 人开始时间: 2022年10月7日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients who enrolled in the Phase I/II Study of Gene Therapy for Parkinson's disease, and who completed or discontinued the study.
排除标准
- •-Patients who cannot undergo MRI.
- •-Individuals who wish to have children, but do not cryopreserve sperm or eggs prior to administration of the investigational product and use them to obtain children.
研究者
相似试验
招募中
不适用
ong-term observational study of Gene Therapy for AADC deficiencyAromatic L-amino acid decarboxylase deficiencyJPRN-jRCT2033220245Yamagata Takanori1
招募中
Unknown
ong-term observational study of Gene Therapy for Sporadic ALSSporadic amyotrophic lateral sclerosis (Sporadic ALS)JPRN-jRCT2033230284Morita Mitsuya6
招募中
1 期
ong-Term Follow-Up (LTFU) for Gene Therapy of Pyruvate Kinase Deficiency (PKD): A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the Codon Optimized Red Cell Pyruvate Kinase (coRPK) Gene in Adult and Pediatric Subjects with PKDPyruvate kinase deficiencyCTIS2022-501526-38-00Rocket Pharmaceuticals Inc.5
进行中（未招募）
1 期
Clinical study to assess the efficacy and safety of gene therapy for the treatment of Sickle Cell DiseaseMedDRA version: 21.0Level: PTClassification code 10040644Term: Sickle cell diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersSickle Cell DiseaseEUCTR2019-000331-63-FRbluebird bio, Inc.35
进行中（未招募）
1 期
Clinical study to assess the efficacy and safety of gene therapy for the treatment of Sickle Cell DiseaseSickle Cell DiseaseEUCTR2019-000331-63-NLbluebird bio, Inc.35